Article

New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review

Author(s):

Davy James, Managing Editor

Top stories of the week on Specialty Pharmacy Times.

[<a href="//storify.com/pharmacytimes/pcsk9-approval-biosimilar-cost" target="_blank">View the story "New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review" on Storify</a>]

Related Videos
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Related Content
Drug Prices, Ozempic, Biktarvy | Image Credit: lucid_dream | stock.adobe.com
January 21st 2025

Ozempic, Biktarvy Among the Drugs Seeing List Price Increases at the Start of 2025

Ashley Gallagher, Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Medical model of chronic kidney disease -- Image credit: kanruthai | stock.adobe.com
January 20th 2025

Study Shows Potential Population-Level Benefits of Intensive BP Targets in Adults With CKD

Gillian McGovern, Associate Editor
Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations
January 25th 2024

Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

Blood sample testing for hepatitis B virus -- Image credit: gamjai | stock.adobe.com
January 17th 2025

Xalnesiran Plus Immunomodulator Results in HBsAg Loss Among Patients With Chronic Hepatitis B

Gillian McGovern, Associate Editor
Precise Pill Time Clock Face Capsules for Medication Management
January 17th 2025

Key Drugs to Watch in Oncology, Hematology, and Neurology for 2025

Luke Halpern, Assistant Editor